The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domain
Open accessAbstract
Multiple human skeletal and craniosynostosis disorders, including Crouzon, Pfeiffer, Jackson–Weiss, and Apert syndromes, result from numerous point mutations in the extracellular region of fibroblast growth factor receptor 2 (FGFR2). Many of these mutations create a free cysteine residue that potentially leads to abnormal disulfide bond formation and receptor activation; however, for noncysteine mutations, the mechanism of receptor activation remains unclear. We examined the effect of two of these mutations, W290G and T341P, on receptor dimerization and activation. These mutations resulted in cellular transformation when expressed as FGFR2/Neu chimeric receptors. Additionally, in full-length FGFR2, the mutations induced receptor dimerization and elevated levels of tyrosine kinase activity. Interestingly, transformation by the chimeric receptors, dimerization, and enhanced kinase activity were all abolished if either the W290G or the T341P mutation was expressed in conjunction with mutations that eliminate the disulfide bond in the third immunoglobulin-like domain (Ig-3). These results demonstrate a requirement for the Ig-3 cysteine residues in the activation of FGFR2 by noncysteine mutations. Molecular modeling also reveals that noncysteine mutations may activate FGFR2 by altering the conformation of the Ig-3 domain near the disulfide bond, preventing the formation of an intramolecular bond. This allows the unbonded cysteine residues to participate in intermolecular disulfide bonding, resulting in constitutive activation of the receptor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signal transduction by receptors with tyrosine kinase activity
Ullrich, A., & Schlessinger, J. (1990) · Cell · doi:10.1016/0092-8674(90)90801-k · Cited by 5,435
A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome
Muenke, M., Schell, U., Hehr, A., Robin, N. H., Losken, H. W., Schinzel, A., Pulleyn, L. J., Rutland, P., Reardon, W., Malcolm, S., et al. (1994) · Nature Genetics · doi:10.1038/ng1194-269 · Cited by 614
Cited by
Mechanisms of receptor tyrosine kinase activation in cancer
Du, Z., & Lovly, C. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0782-4 · Cited by 1,066
Ornitz, D. M., & Marie, P. J. (2002) · Genes & Development · doi:10.1101/gad.990702 · Cited by 905
KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors
Lux, M. L., Rubin, B. P., Biase, T. L., Chen, C.-J., Maclure, T., Demetri, G., Xiao, S., Singer, S., Fletcher, C. D. M., & Fletcher, J. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64946-2 · Cited by 642
Fibroblast growth factors and their receptors in cancer
Wesche, J., Haglund, K., & Haugsten, E. M. (2011) · Biochemical Journal · doi:10.1042/bj20101603 · Cited by 534
Morriss‐Kay, G. M., & Wilkie, A. O. M. (2005) · Journal of Anatomy · doi:10.1111/j.1469-7580.2005.00475.x · Cited by 483
Siegel, P. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2149 · Cited by 442
Genetics of craniofacial development and malformation
Wilkie, A. O. M., & Morriss-Kay, G. M. (2001) · Nature Reviews Genetics · doi:10.1038/35076601 · Cited by 437
Recessive Robinow syndrome, allelic to dominant brachydactyly type B, is caused by mutation of ROR2
Afzal, A. R., Rajab, A., Fenske, C. D., Oldridge, M., Elanko, N., Ternes-Pereira, E., Tüysüz, B., Murday, V. A., Patton, M. A., Wilkie, A. O. M., et al. (2000) · Nature Genetics · doi:10.1038/78107 · Cited by 305
Mansukhani, A., Bellosta, P., Sahni, M., & Basilico, C. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.149.6.1297 · Cited by 295
Clinical spectrum of fibroblast growth factor receptor mutations
Passos-Bueno, M. R., Wilcox, W. R., Jabs, E. W., Serti�, A. L., Alonso, L. G., & Kitoh, H. (1999) · Human Mutation · doi:10.1002/(sici)1098-1004(1999)14:2<115::aid-humu3>3.0.co;2-2 · Cited by 293
A Genetic-Pathophysiological Framework for Craniosynostosis
Twigg, S. R. F., & Wilkie, A. O. M. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.07.006 · Cited by 276
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
Hart, K. C., Robertson, S. C., Kanemitsu, M. Y., Meyer, A. N., Tynan, J. A., & Donoghue, D. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203650 · Cited by 276
Self-citationFibroblast growth factor signaling controlling osteoblast differentiation
Marie, P. J. (2003) · Gene · doi:10.1016/s0378-1119(03)00748-0 · Cited by 274
Kan, S.-H., Elanko, N., Johnson, D., Cornejo-Roldan, L., Cook, J., Reich, E. W., Tomkins, S., Verloes, A., Twigg, S. R. F., Rannan-Eliya, S., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/338758 · Cited by 265
Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome
Yu, K., Herr, A. B., Waksman, G., & Ornitz, D. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.26.14536 · Cited by 258
Wilkie, A. O. M. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.03.001 · Cited by 255
Goriely, A., McVean, G. A. T., van Pelt, A. M. M., O'Rourke, A. W., Wall, S. A., de Rooij, D. G., & Wilkie, A. O. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500267102 · Cited by 146
Bochukova, E. G., Roscioli, T., Hedges, D. J., Taylor, I. B., Johnson, D., David, D. J., Deininger, P. L., & Wilkie, A. O. M. (2009) · Human Mutation · doi:10.1002/humu.20825 · Cited by 66
“In contrast, the FGFR2 mutations causing the other three craniosynostosis syndromes are more widely distributed in both the extracellular and intracellular regions and are constitutively activating [Robertson et al., 1998; Chen et al., 2007a].”
BackgroundHeuzé, Y., Martínez‐Abadías, N., Stella, J. M., Arnaud, E., Collet, C., García Fructuoso, G., Alamar, M., Lo, L., Boyadjiev, S. A., Di Rocco, F., et al. (2014) · Birth Defects Research Part A Clinical and Molecular Teratology · doi:10.1002/bdra.23228 · Cited by 27
Sharma, V. P., Wall, S. A., Lord, H., Lester, T., & Wilkie, A. O. M. (2012) · The Cleft Palate Craniofacial Journal · doi:10.1597/11-185 · Cited by 20
“Building on earlier observations, Robertson et al. (1998) systematically analyzed the consequence of substituting cysteine residues in each of the extracellular domains (IgI, IgII, IgIII) to alanine in FGFR2 (see Fig.”
Background
Metadata
- Authors
- Robertson, S. C., Meyer, A. N., Hart, K. C., Galvin, B. D., Webster, M. K., & Donoghue, D. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1998-04-14
- Volume
- 95
- Issue
- 8
- Pages
- 4567-4572
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1989344307
- Cited by
- 181
- References
- 2
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.